Skip to main content
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 2001 Jun;54(6):435–440. doi: 10.1136/jcp.54.6.435

Hormone replacement therapy and the endometrium

K Feeley 1, M Wells 1
PMCID: PMC1731456  PMID: 11376015

Abstract

Modern hormone replacement therapy (HRT) regimens contain oestrogen and progestogen, given either in a cyclical or continuous combined manner. Most endometrial biopsies from women on sequential HRT show weak secretory features. Approximately 15% show proliferative activity, although this figure may be less if more than nine days of progestogen is given in each cycle. A small proportion will show an inactive or atrophic endometrium. Up to 50% of biopsies from women on continuous combined HRT contain minimal endometrial tissue for histopathological analysis: this correlates well with an atrophic endometrium with no appreciable pathology. Of the 50% with more substantial material, approximately one half will show endometrial atrophy, and one half will show weak secretory features. Proliferative, menstrual, and pseudodecidual changes are rare. Approximately 20% of women given unopposed oestrogen for one year develop endometrial hyperplasia. The relative risk of endometrial carcinoma is two to three. This is dramatically reduced by the addition of progestogen to the regimen, but cyclical progestogen as part of a sequential HRT regimen does not completely eliminate the risk of carcinoma. The prevalence of endometrial hyperplasia associated with sequential HRT is 5.4%, and that of atypical hyperplasia (endometrial intraepithelial neoplasia) is 0.7%. Continuous combined HRT is not associated with the development of hyperplasia or carcinoma, and may normalise the endometrium of women who have developed complex hyperplasia on sequential HRT. The probability of a histopathologist finding clinically relevant pathology in an endometrial biopsy specimen of a patient on HRT is low and is more likely to be a manifestation of pre-existing disease.

Key Words: endometrium • hormone replacement therapy • endometrial hyperplasia • endometrial carcinoma

Full Text

The Full Text of this article is available as a PDF (117.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archer D. F., McIntyre-Seltman K., Wilborn W. W., Jr, Dowling E. A., Cone F., Creasy G. W., Kafrissen M. E. Endometrial morphology in asymptomatic postmenopausal women. Am J Obstet Gynecol. 1991 Aug;165(2):317–322. doi: 10.1016/0002-9378(91)90084-5. [DOI] [PubMed] [Google Scholar]
  2. Archer D. F., Pickar J. H., Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol. 1994 May;83(5 Pt 1):686–692. [PubMed] [Google Scholar]
  3. Barentsen R., Groeneveld F. P., Bareman F. P., Hoes A. W., Dokter H. J., Drogendijk A. C. Women's opinion on withdrawal bleeding with hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol. 1993 Oct 29;51(3):203–207. doi: 10.1016/0028-2243(93)90036-c. [DOI] [PubMed] [Google Scholar]
  4. Batool T., Reginald P. W., Hughes J. H. Outpatient pipelle endometrial biopsy in the investigation of postmenopausal bleeding. Br J Obstet Gynaecol. 1994 Jun;101(6):545–546. doi: 10.1111/j.1471-0528.1994.tb13161.x. [DOI] [PubMed] [Google Scholar]
  5. Beral V., Banks E., Reeves G., Appleby P. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat. 1999;4(3):191–215. [PubMed] [Google Scholar]
  6. Beresford S. A., Weiss N. S., Voigt L. F., McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet. 1997 Feb 15;349(9050):458–461. doi: 10.1016/S0140-6736(96)07365-5. [DOI] [PubMed] [Google Scholar]
  7. Bjarnason K., Cerin A., Lindgren R., Weber T. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. Maturitas. 1999 Aug 16;32(3):161–170. doi: 10.1016/s0378-5122(99)00033-x. [DOI] [PubMed] [Google Scholar]
  8. Brinton L. A., Hoover R. N. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol. 1993 Feb;81(2):265–271. [PubMed] [Google Scholar]
  9. Burch D., Bieshuevel E., Smith S., Fox H. Can endometrial protection be inferred from the bleeding pattern on combined cyclical hormone replacement therapy. Maturitas. 2000 Feb 15;34(2):155–160. doi: 10.1016/s0378-5122(99)00101-2. [DOI] [PubMed] [Google Scholar]
  10. Comerci J. T., Jr, Fields A. L., Runowicz C. D., Goldberg G. L. Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer. Gynecol Oncol. 1997 Mar;64(3):425–430. doi: 10.1006/gyno.1996.4559. [DOI] [PubMed] [Google Scholar]
  11. Cushing K. L., Weiss N. S., Voigt L. F., McKnight B., Beresford S. A. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens. Obstet Gynecol. 1998 Jan;91(1):35–39. doi: 10.1016/s0029-7844(97)00577-2. [DOI] [PubMed] [Google Scholar]
  12. DOCKERTY M. B., JACKSON R. L. The Stein-Leventhal syndrome: analysis of 43 cases with special reference to association with endometrial carcinoma. Am J Obstet Gynecol. 1957 Jan;73(1):161–173. [PubMed] [Google Scholar]
  13. Dören M., Schneider H. P. Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women. Maturitas. 1996 Oct;25(2):99–105. doi: 10.1016/0378-5122(96)01048-1. [DOI] [PubMed] [Google Scholar]
  14. Ferenczy A., Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol. 1989 Jan;160(1):126–131. doi: 10.1016/0002-9378(89)90103-8. [DOI] [PubMed] [Google Scholar]
  15. Fothergill D. J., Brown V. A., Hill A. S. Histological sampling of the endometrium--a comparison between formal curettage and the Pipelle sampler. Br J Obstet Gynaecol. 1992 Sep;99(9):779–780. doi: 10.1111/j.1471-0528.1992.tb13887.x. [DOI] [PubMed] [Google Scholar]
  16. Gelfand M. M., Ferenczy A. A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium. Obstet Gynecol. 1989 Sep;74(3 Pt 1):398–402. [PubMed] [Google Scholar]
  17. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995 Feb;85(2):304–313. doi: 10.1016/0029-7844(94)00383-O. [DOI] [PubMed] [Google Scholar]
  18. Habiba M. A., Bell S. C., Al-Azzawi F. Endometrial responses to hormone replacement therapy: histological features compared with those of late luteal phase endometrium. Hum Reprod. 1998 Jun;13(6):1674–1682. doi: 10.1093/humrep/13.6.1674. [DOI] [PubMed] [Google Scholar]
  19. Hahn R. G. Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am J Obstet Gynecol. 1989 Dec;161(6 Pt 2):1854–1858. doi: 10.1016/s0002-9378(89)80006-7. [DOI] [PubMed] [Google Scholar]
  20. Hammond C. B., Jelovsek F. R., Lee K. L., Creasman W. T., Parker R. T. Effects of long-term estrogen replacement therapy. II. Neoplasia. Am J Obstet Gynecol. 1979 Mar 1;133(5):537–547. doi: 10.1016/0002-9378(79)90289-8. [DOI] [PubMed] [Google Scholar]
  21. Hawthorn R. J., Spowart K., Walsh D., Hart D. M. The endometrial status of women on long-term continuous combined hormone replacement therapy. Br J Obstet Gynaecol. 1991 Sep;98(9):939–940. doi: 10.1111/j.1471-0528.1991.tb13519.x. [DOI] [PubMed] [Google Scholar]
  22. Hillard T. C., Siddle N. C., Whitehead M. I., Fraser D. I., Pryse-Davies J. Continuous combined conjugated equine estrogen-progestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis. Am J Obstet Gynecol. 1992 Jul;167(1):1–7. doi: 10.1016/s0002-9378(11)91614-7. [DOI] [PubMed] [Google Scholar]
  23. Kennedy M. M., Baigrie C. F., Manek S. Tamoxifen and the endometrium: review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology. Int J Gynecol Pathol. 1999 Apr;18(2):130–137. [PubMed] [Google Scholar]
  24. King R. J., Whitehead M. I., Campbell S., Minardi J. Biochemical studies on endometrium from postmenopausal women receiving hormone replacement therapy. Postgrad Med J. 1978;54 (Suppl 2):65–68. [PubMed] [Google Scholar]
  25. Korhonen M. O., Symons J. P., Hyde B. M., Rowan J. P., Wilborn W. H. Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol. 1997 Feb;176(2):377–380. doi: 10.1016/s0002-9378(97)70502-7. [DOI] [PubMed] [Google Scholar]
  26. Kurman R. J., Kaminski P. F., Norris H. J. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985 Jul 15;56(2):403–412. doi: 10.1002/1097-0142(19850715)56:2<403::aid-cncr2820560233>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  27. Leather A. T., Savvas M., Studd J. W. Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol. 1991 Dec;78(6):1008–1010. [PubMed] [Google Scholar]
  28. Levi F., La Vecchia C., Gulie C., Franceschi S., Negri E. Oestrogen replacement treatment and the risk of endometrial cancer: an assessment of the role of covariates. Eur J Cancer. 1993;29A(10):1445–1449. doi: 10.1016/0959-8049(93)90018-b. [DOI] [PubMed] [Google Scholar]
  29. MANSELL H., HERTIG A. T. Granulosatheca cell tumors and endometrial carcinoma; a study of their relationship and a survey of 80 cases. Obstet Gynecol. 1955 Oct;6(4):385–394. [PubMed] [Google Scholar]
  30. Mack T. M., Pike M. C., Henderson B. E., Pfeffer R. I., Gerkins V. R., Arthur M., Brown S. E. Estrogens and endometrial cancer in a retirement community. N Engl J Med. 1976 Jun 3;294(23):1262–1267. doi: 10.1056/NEJM197606032942304. [DOI] [PubMed] [Google Scholar]
  31. Maia H., Jr, Barbosa I. C., Marques D., Calmon L. C., Ladipo O. A., Coutinho E. M. Hysteroscopy and transvaginal sonography in menopausal women receiving hormone replacement therapy. J Am Assoc Gynecol Laparosc. 1996 Nov;4(1):13–18. doi: 10.1016/s1074-3804(96)80102-2. [DOI] [PubMed] [Google Scholar]
  32. Mattsson L. A., Cullberg G., Samsioe G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas. 1982 Aug;4(2):95–102. doi: 10.1016/0378-5122(82)90035-4. [DOI] [PubMed] [Google Scholar]
  33. McGonigle K. F., Karlan B. Y., Barbuto D. A., Leuchter R. S., Lagasse L. D., Judd H. L. Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy. Gynecol Oncol. 1994 Oct;55(1):126–132. doi: 10.1006/gyno.1994.1261. [DOI] [PubMed] [Google Scholar]
  34. Moyer D. L., de Lignieres B., Driguez P., Pez J. P. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril. 1993 May;59(5):992–997. doi: 10.1016/s0015-0282(16)55916-0. [DOI] [PubMed] [Google Scholar]
  35. Mutter G. L., Baak J. P., Crum C. P., Richart R. M., Ferenczy A., Faquin W. C. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol. 2000 Mar;190(4):462–469. doi: 10.1002/(SICI)1096-9896(200003)190:4<462::AID-PATH590>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  36. Mutter G. L. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol. 2000 Mar;76(3):287–290. doi: 10.1006/gyno.1999.5580. [DOI] [PubMed] [Google Scholar]
  37. Nand S. L., Webster M. A., Baber R., O'Connor V. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group. Obstet Gynecol. 1998 May;91(5 Pt 1):678–684. doi: 10.1016/s0029-7844(98)00038-6. [DOI] [PubMed] [Google Scholar]
  38. Obel E. B., Munk-Jensen N., Svenstrup B., Bennett P., Micic S., Henrik-Nielsen R., Nielsen S. P., Gydesen H., Jensen B. M. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment. Maturitas. 1993 Jan;16(1):13–21. doi: 10.1016/0378-5122(93)90129-6. [DOI] [PubMed] [Google Scholar]
  39. Orvieto R., Bar-Hava I., Dicker D., Bar J., Ben-Rafael Z., Neri A. Endometrial polyps during menopause: characterization and significance. Acta Obstet Gynecol Scand. 1999 Nov;78(10):883–886. [PubMed] [Google Scholar]
  40. Padwick M. L., Pryse-Davies J., Whitehead M. I. A simple method for determining the optimal dosage of progestin in postmenopausal women receiving estrogens. N Engl J Med. 1986 Oct 9;315(15):930–934. doi: 10.1056/NEJM198610093151504. [DOI] [PubMed] [Google Scholar]
  41. Paganini-Hill A., Ross R. K., Henderson B. E. Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer. 1989 Mar;59(3):445–447. doi: 10.1038/bjc.1989.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Paterson M. E., Wade-Evans T., Sturdee D. W., Thom M. H., Studd J. W. Endometrial disease after treatment with oestrogens and progestogens in the climacteric. Br Med J. 1980 Mar 22;280(6217):822–824. doi: 10.1136/bmj.280.6217.822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Persson I., Adami H. O., Bergkvist L., Lindgren A., Pettersson B., Hoover R., Schairer C. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ. 1989 Jan 21;298(6667):147–151. doi: 10.1136/bmj.298.6667.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Persson I., Yuen J., Bergkvist L., Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort. Int J Cancer. 1996 Jul 29;67(3):327–332. doi: 10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  45. Piegsa K., Calder A., Davis J. A., McKay-Hart D., Wells M., Bryden F. Endometrial status in post-menopausal women on long-term continuous combined hormone replacement therapy (Kliofem). A comparative study of endometrial biopsy, outpatient hysteroscopy and transvaginal ultrasound. Eur J Obstet Gynecol Reprod Biol. 1997 Apr;72(2):175–180. doi: 10.1016/s0301-2115(96)02670-x. [DOI] [PubMed] [Google Scholar]
  46. Pike M. C., Peters R. K., Cozen W., Probst-Hensch N. M., Felix J. C., Wan P. C., Mack T. M. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997 Aug 6;89(15):1110–1116. doi: 10.1093/jnci/89.15.1110. [DOI] [PubMed] [Google Scholar]
  47. Rees M. On menstrual bleeding with hormone replacement therapy. Lancet. 1994 Jan 29;343(8892):250–250. doi: 10.1016/s0140-6736(94)91108-8. [DOI] [PubMed] [Google Scholar]
  48. Rubin G. L., Peterson H. B., Lee N. C., Maes E. F., Wingo P. A., Becker S. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol. 1990 Jan;162(1):148–154. doi: 10.1016/0002-9378(90)90838-x. [DOI] [PubMed] [Google Scholar]
  49. Shapiro S., Kaufman D. W., Slone D., Rosenberg L., Miettinen O. S., Stolley P. D., Rosenshein N. B., Watring W. G., Leavitt T., Jr, Knapp R. C. Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium. N Engl J Med. 1980 Aug 28;303(9):485–489. doi: 10.1056/NEJM198008283030903. [DOI] [PubMed] [Google Scholar]
  50. Shapiro S., Kelly J. P., Rosenberg L., Kaufman D. W., Helmrich S. P., Rosenshein N. B., Lewis J. L., Jr, Knapp R. C., Stolley P. D., Schottenfeld D. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med. 1985 Oct 17;313(16):969–972. doi: 10.1056/NEJM198510173131601. [DOI] [PubMed] [Google Scholar]
  51. Smith D. C., Prentice R., Thompson D. J., Herrmann W. L. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975 Dec 4;293(23):1164–1167. doi: 10.1056/NEJM197512042932302. [DOI] [PubMed] [Google Scholar]
  52. Spengler R. F., Clarke E. A., Woolever C. A., Newman A. M., Osborn R. W. Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases. Am J Epidemiol. 1981 Oct;114(4):497–506. doi: 10.1093/oxfordjournals.aje.a113215. [DOI] [PubMed] [Google Scholar]
  53. Sporrong T., Hellgren M., Samsioe G., Mattsson L. A. Comparison of four continuously administered progestogen plus oestradiol combinations for climacteric complaints. Br J Obstet Gynaecol. 1988 Oct;95(10):1042–1048. doi: 10.1111/j.1471-0528.1988.tb06511.x. [DOI] [PubMed] [Google Scholar]
  54. Stadberg E., Mattsson L. A., Uvebrant M. 17 beta-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. Maturitas. 1996 Feb;23(1):31–39. doi: 10.1016/0378-5122(95)00949-3. [DOI] [PubMed] [Google Scholar]
  55. Staland B. Continuous treatment with a combination of estrogen and gestagen--a way of avoiding endometrial stimulation. Clinical experiences with Kliogest. Acta Obstet Gynecol Scand Suppl. 1985;130:29–35. doi: 10.3109/00016348509157144. [DOI] [PubMed] [Google Scholar]
  56. Staland B. Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. Maturitas. 1981 Aug;3(2):145–156. doi: 10.1016/0378-5122(81)90006-2. [DOI] [PubMed] [Google Scholar]
  57. Stovall T. G., Photopulos G. J., Poston W. M., Ling F. W., Sandles L. G. Pipelle endometrial sampling in patients with known endometrial carcinoma. Obstet Gynecol. 1991 Jun;77(6):954–956. [PubMed] [Google Scholar]
  58. Sturdee D. W., Barlow D. H., Ulrich L. G., Wells M., Gydesen H., Campbell M., O'Brien K., Vessey M. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy? UK Continuous Combined HRT Study Investigators. Lancet. 1994 Oct 8;344(8928):979–982. doi: 10.1016/s0140-6736(94)91640-3. [DOI] [PubMed] [Google Scholar]
  59. Sturdee D. W., Ulrich L. G., Barlow D. H., Wells M., Campbell M. J., Vessey M. P., Nielsen B., Anderson M. C., Bragg A. J. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. BJOG. 2000 Nov;107(11):1392–1400. doi: 10.1111/j.1471-0528.2000.tb11654.x. [DOI] [PubMed] [Google Scholar]
  60. Udoff L., Langenberg P., Adashi E. Y. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol. 1995 Aug;86(2):306–316. doi: 10.1016/0029-7844(95)00115-8. [DOI] [PubMed] [Google Scholar]
  61. Ulrich L. G. Accumulated knowledge of Kliogest safety aspects. Br J Obstet Gynaecol. 1996 May;103 (Suppl 13):99–103. [PubMed] [Google Scholar]
  62. Voigt L. F., Weiss N. S., Chu J., Daling J. R., McKnight B., van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet. 1991 Aug 3;338(8762):274–277. doi: 10.1016/0140-6736(91)90417-n. [DOI] [PubMed] [Google Scholar]
  63. Weiderpass E., Adami H. O., Baron J. A., Magnusson C., Bergström R., Lindgren A., Correia N., Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst. 1999 Jul 7;91(13):1131–1137. doi: 10.1093/jnci/91.13.1131. [DOI] [PubMed] [Google Scholar]
  64. Weinstein L., Bewtra C., Gallagher J. C. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol. 1990 Jun;162(6):1534–1542. doi: 10.1016/0002-9378(90)90917-v. [DOI] [PubMed] [Google Scholar]
  65. Weiss N. S., Szekely D. R., Austin D. F. Increasing incidence of endometrial cancer in the United States. N Engl J Med. 1976 Jun 3;294(23):1259–1262. doi: 10.1056/NEJM197606032942303. [DOI] [PubMed] [Google Scholar]
  66. Whitehead M. I., Hillard T. C., Crook D. The role and use of progestogens. Obstet Gynecol. 1990 Apr;75(4 Suppl):59S–83S. [PubMed] [Google Scholar]
  67. Whitehead M. I., King R. J., McQueen J., Campbell S. Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestogen therapy. J R Soc Med. 1979 May;72(5):322–327. doi: 10.1177/014107687907200504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Woodruff J. D., Pickar J. H. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol. 1994 May;170(5 Pt 1):1213–1223. doi: 10.1016/s0002-9378(94)70129-6. [DOI] [PubMed] [Google Scholar]
  69. Ziel H. K., Finkle W. D. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975 Dec 4;293(23):1167–1170. doi: 10.1056/NEJM197512042932303. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES